Andrew Satlin, MD

Articles by Andrew Satlin, MD

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

July 23rd 2018

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

Latest Updated Articles

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Published: July 23rd 2018 | Updated:

Andrew Satlin, MD

Articles by Andrew Satlin, MD

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials

B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial

Independent Adjudication Committee Helps Facilitate Accurate Enrollment of Phase 2/3 ARISE Trial of Nipocalimab